ARTICLES BY LOUIS

• Pfizer Shifts Outsourcing And Communication To Fight COVID-19

  Pfizer’s speaking in real-time – actually forward-looking pronouncements of manufacturing intentions and locations – is refreshing, and should be applauded. Does this represent an industry "shift"?

• As Your CDMOs Grow In Value, Their Challenges Pile Up

  The CDMO market is estimated to grow to $157.7 billion in 2025, a compound annual growth rate (CAGR) of 6.9%, according to an industry report. But what kind of CDMO growth is best for Outsourced Pharma readers?

• The Raw Materials Of A Supply-Chain Revolution

  To diversify China-dependent supply chains and procure materials, API and products in the U.S., we'd literally need to start digging.

• Question Your Buyer Motivation And Supply-Chain Origins

  Don Buckner left a comment to my recent '50 By 25" editorial: “Will have success if the buyers demand it.” I liked the idea of buyer-driven demand as a path to explore your supply-chain decisions. It also led to some fundamental questions of your motivations.

• A COVID-19 Vaccine, Outsourcing, And Made In The USA

  That’s an unwieldy title for an editorial. But we’ll bundle those three components quickly, thanks to U.S.-based GeoVax Labs CEO David Dodd. He's the quintessential professional to assist readers in assessing and contemplating current and future realities.

• “Who Are They?” A Biotech CEO’s Timeless Question For CDMOs

  The questions James E. Brown, President & CEO, DURECT, asked of CDMOs when he founded the company in 1998 remain perfectly operational: "Who are they? Where did those individuals come from? What are their personal track records?”

• “Political” Supply-Chain Decisions In Time Of Crisis

  At this time of difficult political, economic, and health-related decision-making, the entire nation needs your practiced mix of data centrality, and your experience in partnerships and (supply-chain) systems where qualitative analysis also play a major role.

• Shared Responsibility: A Millennial’s Outsourcing Strategy

  We featured Sara McCutchan in an earlier editorial, "A Path To Biotech For Young Women." Here she provides strong examples and best practices for small biotechs reliant on outsourcing drug development to CDMOs.

• Inserting The Pharmacist At The Center Of Biopharma

  The president of a college of pharmacy believes pharmacy graduates should occupy the center of the biopharma drug development and manufacturing industry. In fact, quite a few do already. More are on the way.

• Sign The “50 By 25” Declaration Of Drug Independence

  Will you become a founding signatory to the aggressive but realistic, "U.S. '50 By 25' Declaration Of Drug Independence"? And dedicate yourself to the goal of reducing dependency on foreign sources for drug materials, intermediates, substances?